These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3182453)

  • 21. Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers.
    Guay DR; Opsahl JA; McMahon FG; Vargas R; Matzke GR; Flor S
    Antimicrob Agents Chemother; 1992 Feb; 36(2):308-12. PubMed ID: 1605596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of ofloxacin in elderly patients and in healthy young subjects.
    Molinaro M; Villani P; Regazzi MB; Rondanelli R; Doveri G
    Eur J Clin Pharmacol; 1992; 43(1):105-7. PubMed ID: 1505603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ofloxacin in urinary tract infections.
    Kromann-Andersen B; Krøyer Nielsen K
    Scand J Infect Dis Suppl; 1990; 68():35-40. PubMed ID: 2218420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers.
    Agarwal S; Solomon WD; Gowda KV; Selvan PS; Ghosh D; Sarkar AK; Chattaraj TK; Pal TK
    Arzneimittelforschung; 2007; 57(10):679-83. PubMed ID: 18074762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of ofloxacin and a review of its tissue penetration.
    Wise R; Lockley MR
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():59-64. PubMed ID: 3182463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enterobacteriaceae suppression by three different oral doses of polymyxin E in human volunteers.
    van Saene JJ; van Saene HK; Tarko-Smit NJ; Beukeveld GJ
    Epidemiol Infect; 1988 Jun; 100(3):407-17. PubMed ID: 3378584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.
    Guay D; Tack K; Flor S
    Int J Clin Pharmacol Res; 1991; 11(5):203-9. PubMed ID: 1814841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ofloxacin concentrations in tissues involved in respiratory tract infections.
    Perea EJ
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():55-60. PubMed ID: 2286591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.
    White LO; MacGowan AP; Mackay IG; Reeves DS
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():65-72. PubMed ID: 3182464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ofloxacin and the gastrointestinal tract: a potential role in the treatment of bacterial enteritis.
    Lang R; Lishner M; Segev S; Rubinstein E
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():45-53. PubMed ID: 2286590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers.
    Fillastre JP; Leroy A; Borsa-Lebas F; Etienne I; Gy C; Humbert G
    Drugs Exp Clin Res; 1992; 18(11-12):487-92. PubMed ID: 1308475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
    Walters T; Rinehart M; Krebs W; Holdbrook M
    Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy.
    Brown NM; White LO; Blundell EL; Chown SR; Slade RR; MacGowan AP; Reeves DS
    J Antimicrob Chemother; 1993 Jul; 32(1):117-22. PubMed ID: 8226402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of a single oral dose of ofloxacin in patients with renal failure.
    Nawishy S; Moukhtar I; Sabbour M
    Chemioterapia; 1986 Dec; 5(6):391-3. PubMed ID: 3467875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers.
    Bächer K; Schaeffer M; Lode H; Nord CE; Borner K; Koeppe P
    J Antimicrob Chemother; 1992 Sep; 30(3):365-75. PubMed ID: 1452502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Pharmatherapeutica; 1985; 4(6):376-82. PubMed ID: 3866256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of levofloxacin in healthy Thai male volunteers.
    Chulavatnatol S; Chindavijak B; Vibhagool A; Wananukul W; Sriapha C; Sirisangtragul C
    J Med Assoc Thai; 1999 Nov; 82(11):1127-35. PubMed ID: 10659548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis.
    Kampf D; Borner K; Pustelnik A
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():61-8. PubMed ID: 2286592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, urinary excretion and plasma protein binding of ofloxacin in water buffalo calves (Bubalus bubalis).
    Ola AK; Sandhu HS; Dumka VK; Ranjan B
    J S Afr Vet Assoc; 2013 Apr; 84(1):E1-5. PubMed ID: 23718538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.